Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michiel van de Sande

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|September 29, 2021
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumorOphelia Yin, Hamim Zahir, Jonathan French, et al.
The Oncologist|March 4, 2023
Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment StrategiesEmanuela Palmerini, John H Healey, Nicholas M Bernthal, et al.
Clinical Orthopaedics and Related Research|August 24, 2022
Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVENJohn H Healey, William D Tap, Heather L Gelhorn, et al.
The Oncologist|December 8, 2020
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell TumorsJames H Lewis, Hans Gelderblom, Michiel van de Sande, et al.
Acta Orthopaedica|May 12, 2021
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trialMichiel Van De Sande, William D Tap, Heather L Gelhorn, et al.
Journal of Surgical Oncology|August 25, 2022
A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysisNicholas M Bernthal, John H Healey, Emanuela Palmerini, et al.
The Oncologist|July 4, 2025
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN studyAndrew J Wagner, William D Tap, Sebastian Bauer, et al.
Journal of Surgical Oncology|June 8, 2020
Expandable distal femur megaprosthesis: A European Musculoskeletal Oncology Society study on 299 casesEric Lodewijk Staals, Andrea Sambri, Domenico Andrea Campanacci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of VimseltinibHans Gelderblom, Albiruni A Razak, Matthew H Taylor, et al.
Lancet (London, England)|June 24, 2019
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D Tap, Hans Gelderblom, Emanuela Palmerini, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
CPT: Pharmacometrics & Systems Pharmacology|September 29, 2021
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumorOphelia Yin, Hamim Zahir, Jonathan French, et al.
The Oncologist|March 4, 2023
Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment StrategiesEmanuela Palmerini, John H Healey, Nicholas M Bernthal, et al.
Clinical Orthopaedics and Related Research|August 24, 2022
Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVENJohn H Healey, William D Tap, Heather L Gelhorn, et al.
The Oncologist|December 8, 2020
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell TumorsJames H Lewis, Hans Gelderblom, Michiel van de Sande, et al.
Acta Orthopaedica|May 12, 2021
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trialMichiel Van De Sande, William D Tap, Heather L Gelhorn, et al.
Journal of Surgical Oncology|August 25, 2022
A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysisNicholas M Bernthal, John H Healey, Emanuela Palmerini, et al.
The Oncologist|July 4, 2025
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN studyAndrew J Wagner, William D Tap, Sebastian Bauer, et al.
Journal of Surgical Oncology|June 8, 2020
Expandable distal femur megaprosthesis: A European Musculoskeletal Oncology Society study on 299 casesEric Lodewijk Staals, Andrea Sambri, Domenico Andrea Campanacci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of VimseltinibHans Gelderblom, Albiruni A Razak, Matthew H Taylor, et al.
Lancet (London, England)|June 24, 2019
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D Tap, Hans Gelderblom, Emanuela Palmerini, et al.
Pageof 4